vs

Side-by-side financial comparison of Ginkgo Bioworks Holdings, Inc. (DNA) and RICHARDSON ELECTRONICS, LTD. (RELL). Click either name above to swap in a different company.

RICHARDSON ELECTRONICS, LTD. is the larger business by last-quarter revenue ($52.3M vs $33.4M, roughly 1.6× Ginkgo Bioworks Holdings, Inc.). On growth, RICHARDSON ELECTRONICS, LTD. posted the faster year-over-year revenue change (5.7% vs -23.8%). RICHARDSON ELECTRONICS, LTD. produced more free cash flow last quarter ($-1.7M vs $-47.7M). Over the past eight quarters, RICHARDSON ELECTRONICS, LTD.'s revenue compounded faster (-0.3% CAGR vs -6.2%).

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It...

The James Richardson Corporation, also going by the name James Richardson Group or JR/Group, is an Australian furniture, hospitality, real estate and retail corporation, headquartered in the Abbotsford suburb of Melbourne, Australia. It is privately owned and employs approximately 2,300 people worldwide. It is perhaps best known among consumers for its duty-free retail stores in airports and border crossings in Australasia and the Middle East. The company is a household name in Israel due to ...

DNA vs RELL — Head-to-Head

Bigger by revenue
RELL
RELL
1.6× larger
RELL
$52.3M
$33.4M
DNA
Growing faster (revenue YoY)
RELL
RELL
+29.5% gap
RELL
5.7%
-23.8%
DNA
More free cash flow
RELL
RELL
$46.0M more FCF
RELL
$-1.7M
$-47.7M
DNA
Faster 2-yr revenue CAGR
RELL
RELL
Annualised
RELL
-0.3%
-6.2%
DNA

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
DNA
DNA
RELL
RELL
Revenue
$33.4M
$52.3M
Net Profit
$-121.0K
Gross Margin
30.7%
Operating Margin
-211.9%
0.3%
Net Margin
-0.2%
Revenue YoY
-23.8%
5.7%
Net Profit YoY
83.9%
EPS (diluted)
$-1.41

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DNA
DNA
RELL
RELL
Q4 25
$33.4M
$52.3M
Q3 25
$38.8M
$54.6M
Q2 25
$49.6M
Q1 25
$48.3M
$53.8M
Q4 24
$43.8M
$49.5M
Q3 24
$89.0M
$53.7M
Q2 24
$56.2M
Q1 24
$37.9M
$52.4M
Net Profit
DNA
DNA
RELL
RELL
Q4 25
$-121.0K
Q3 25
$-80.8M
$1.9M
Q2 25
$-60.3M
Q1 25
$-91.0M
$-2.1M
Q4 24
$-751.0K
Q3 24
$-56.4M
$590.0K
Q2 24
$-217.2M
Q1 24
$-165.9M
$750.0K
Gross Margin
DNA
DNA
RELL
RELL
Q4 25
30.7%
Q3 25
31.0%
Q2 25
Q1 25
31.0%
Q4 24
31.0%
Q3 24
30.6%
Q2 24
Q1 24
29.5%
Operating Margin
DNA
DNA
RELL
RELL
Q4 25
-211.9%
0.3%
Q3 25
-231.8%
1.8%
Q2 25
-132.1%
Q1 25
-184.1%
-5.1%
Q4 24
-236.3%
-1.3%
Q3 24
-62.0%
0.6%
Q2 24
-396.7%
Q1 24
-469.1%
1.9%
Net Margin
DNA
DNA
RELL
RELL
Q4 25
-0.2%
Q3 25
-207.9%
3.5%
Q2 25
-121.6%
Q1 25
-188.2%
-3.8%
Q4 24
-1.5%
Q3 24
-63.3%
1.1%
Q2 24
-386.4%
Q1 24
-437.3%
1.4%
EPS (diluted)
DNA
DNA
RELL
RELL
Q4 25
$-1.41
Q3 25
$-1.45
Q2 25
$-1.10
Q1 25
$-1.68
Q4 24
$-1.91
Q3 24
$-1.08
Q2 24
$-4.23
Q1 24
$-3.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DNA
DNA
RELL
RELL
Cash + ST InvestmentsLiquidity on hand
$422.6M
$33.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$508.6M
$158.5M
Total Assets
$1.1B
$201.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DNA
DNA
RELL
RELL
Q4 25
$422.6M
$33.1M
Q3 25
$495.5M
$35.7M
Q2 25
$559.4M
Q1 25
$325.3M
$36.7M
Q4 24
$561.6M
$26.6M
Q3 24
$616.2M
$23.0M
Q2 24
$730.4M
Q1 24
$840.4M
$18.9M
Stockholders' Equity
DNA
DNA
RELL
RELL
Q4 25
$508.6M
$158.5M
Q3 25
$559.8M
$159.4M
Q2 25
$613.0M
Q1 25
$647.4M
$152.9M
Q4 24
$716.1M
$156.2M
Q3 24
$797.9M
$159.1M
Q2 24
$833.1M
Q1 24
$987.3M
$158.6M
Total Assets
DNA
DNA
RELL
RELL
Q4 25
$1.1B
$201.8M
Q3 25
$1.2B
$200.1M
Q2 25
$1.2B
Q1 25
$1.3B
$189.8M
Q4 24
$1.4B
$195.2M
Q3 24
$1.5B
$197.9M
Q2 24
$1.6B
Q1 24
$1.6B
$193.6M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DNA
DNA
RELL
RELL
Operating Cash FlowLast quarter
$-47.7M
$-99.0K
Free Cash FlowOCF − Capex
$-47.7M
$-1.7M
FCF MarginFCF / Revenue
-142.8%
-3.3%
Capex IntensityCapex / Revenue
0.0%
3.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$7.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DNA
DNA
RELL
RELL
Q4 25
$-47.7M
$-99.0K
Q3 25
$-31.6M
$1.4M
Q2 25
$-40.3M
Q1 25
$-51.5M
$4.6M
Q4 24
$-42.4M
$5.5M
Q3 24
$-103.5M
$412.0K
Q2 24
$-84.4M
Q1 24
$-89.3M
$-2.5M
Free Cash Flow
DNA
DNA
RELL
RELL
Q4 25
$-47.7M
$-1.7M
Q3 25
$342.0K
Q2 25
$-40.3M
Q1 25
$-59.1M
$4.1M
Q4 24
$-56.1M
$4.9M
Q3 24
$-118.6M
$-514.0K
Q2 24
$-111.4M
Q1 24
$-96.0M
$-2.9M
FCF Margin
DNA
DNA
RELL
RELL
Q4 25
-142.8%
-3.3%
Q3 25
0.6%
Q2 25
-81.2%
Q1 25
-122.4%
7.5%
Q4 24
-128.0%
10.0%
Q3 24
-133.2%
-1.0%
Q2 24
-198.2%
Q1 24
-252.9%
-5.6%
Capex Intensity
DNA
DNA
RELL
RELL
Q4 25
0.0%
3.1%
Q3 25
0.0%
1.9%
Q2 25
0.1%
Q1 25
15.8%
1.0%
Q4 24
31.3%
1.0%
Q3 24
16.9%
1.7%
Q2 24
48.1%
Q1 24
17.7%
0.8%
Cash Conversion
DNA
DNA
RELL
RELL
Q4 25
Q3 25
0.72×
Q2 25
Q1 25
Q4 24
Q3 24
0.70×
Q2 24
Q1 24
-3.37×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DNA
DNA

Cell Engineering Segment$26.0M78%
Other$7.4M22%

RELL
RELL

Power And Microwave Technologies Group$35.2M67%
Canvys$8.8M17%
Global Energy Solutions$8.3M16%

Related Comparisons